Insider Buying: Aquinox Pharmaceuticals Inc. (AQXP) Major Shareholder Purchases 2,783,605 Shares of Stock
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 1.49% during midday trading on Wednesday, hitting $13.63. The stock had a trading volume of 525,278 shares. The stock has a 50 day moving average of $10.77 and a 200 day moving average of $8.69. Aquinox Pharmaceuticals Inc. has a 12 month low of $6.01 and a 12 month high of $18.85. The stock’s market cap is $234.60 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.22. Analysts expect that Aquinox Pharmaceuticals Inc. will post ($2.11) EPS for the current fiscal year.
Several equities research analysts have weighed in on AQXP shares. Jefferies Group increased their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 21st. Finally, Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $19.86.
Several institutional investors have recently made changes to their positions in AQXP. Franklin Resources Inc. increased its position in Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares in the last quarter. BlackRock Inc. increased its position in Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock worth $446,000 after buying an additional 9,900 shares in the last quarter. Royce & Associates LP increased its position in Aquinox Pharmaceuticals by 416.4% in the first quarter. Royce & Associates LP now owns 96,167 shares of the company’s stock worth $848,000 after buying an additional 77,545 shares in the last quarter. Finally, BlackRock Group LTD increased its position in Aquinox Pharmaceuticals by 23.4% in the first quarter. BlackRock Group LTD now owns 200,100 shares of the company’s stock worth $1,765,000 after buying an additional 37,900 shares in the last quarter. 89.41% of the stock is currently owned by institutional investors and hedge funds.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.